A Phase 1, Multicenter, Open-Label, Dose-Escalation and Expansion, Safety, Pharmacokinetic, Pharmacodynamic, and Clinical Activity Study of Orally Administered AG-881 in Patients with Advanced Solid Tumors, Including Gliomas, with an IDH1 and/or IDH2 Mutation
The goal of this clinical research study is to find the highest tolerable dose of AG-881 that can be given to patients with a solid tumor. The safety of this drug will also be studied.
Treatment Location: N/A
IRB Review and Approval Date: 09/08/2015
Recruitment Status: Closed
Projected Accrual: N/A
Information and next steps
For general questions about clinical trials: